



PROGRAM

Time Aus EDST	Speaker/s		Affiliation	
8:30-8:40	AVS President	Prof Heidi Drummer	Burnet Institute	
		AVS meets ASV		Title
8:40-8:55am	2023 ASV Ann Palmenberg Junior Investigator	Dr Siyuan Ding	Washington University, USA	NSP1 antagonism of interferon signaling: a sage of rotavirus-host arms race
8:55-9:10am	AVS Rising Star	Dr Ebony Monson	La Trobe University, Australia	The role of lipid droplets in antiviral immunity.
9:10-9:25am	2023 ASV Ann Palmenberg Junior Investigator	Dr Kellie Jurado	University of Pennsylvania, USA	IL27 is an antiviral cytokine during congenital infection
9:25-9:55am	Invited Speaker	A/Prof Stuart Turville	The Kirby Institute, UNSW, Australia	Engineering tools for rapid viral tracking
10:00-10:40am		<i>Break</i>		
10:40-11:10am	Invited Speaker	Steve Wesselingh	NHMRC CEO	
11:10-11:25am	Abstract selected oral presentation	Xiaohui Wang	Institute for Molecular Biosciences	Targeting pro-inflammatory epithelial-macrophage crosstalk to alleviate immunopathology during IAV infection
11:25-11:40am		Wilson Nguyen	QIMR Berghofer Medical Research Institute	A chimeric vaccine protects mice against lethal challenge of the Australian genotype IV strain of Japanese encephalitis virus and provides cross-protection against Murray Valley encephalitis virus.
11:40-11:55am		Xavier Montin	University of Adelaide	Understanding the AhR and Innate Immunity Axis in RNA Virus Infection
11:55-1:00pm		<i>Lunch Break</i>		
1:00-2:15pm		Annual General Meeting (AGM)		



PROGRAM CONTINUED

Time Aus EDST	Speaker/s	Affiliation	Title
2:15-2:45pm	Samaneh Moallemi	Faculty of Medicine, University of New South Wales	Early biomarkers for prediction of severe manifestations of dengue fever: a systematic review and a meta-analysis.
	Lewis K Mercer	Faculty of Science, University of New South Wales	The reemergence of pandemic noroviruses during the COVID-19 pandemic: Norovirus molecular epidemiology in NSW 2021 – 2022
	Thomas Burton	The Peter Doherty Institute for Infection and Immunity	Identification of a potent dengue virus inhibitor using a virtual compound screen.
	Caitlin O'Brien	CSIRO Australian Centre for Disease Preparedness	Vector and host-dynamics of Japanese encephalitis virus Genotype IV Major Advances in Virology
	Arunasingam Abayasingam	The Kirby Institute, UNSW	Immunogenicity and Neutralisation Sensitivity of Hepatitis C Virus Transmitted/Founder Variants: Implications for Vaccine Design
	Roman Lenchine	Flinders University	Investigating the mechanisms of action of the dengue virus inhibitor JNJ-A07
	Abigail Cox	QIMR Berghofer	Japanese Encephalitis Virus Sensitivity to Interferon Responses
	Joey McGregor	Burnet Institute	Development of mRNA vaccines for Hepatitis C virus
	Jay Laws	La Trobe University	The lipid droplet recruits antiviral signalling proteins following cellular viral infection
2:45-3:00pm	AVS President-Elect		